Acromegaly

Pituitary

Volumn 9, Issue 4, 2006, Pages 297-303

  Scacchi, Massimo ^a   Cavagnini, Francesco ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Acromegaly; Diagnosis; GH; IGF I; Treatment

Indexed keywords

ANGIOPEPTIN; BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; GADOLINIUM; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; OCTREOTIDE; PEGVISOMANT; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE;

ABDOMINAL DISCOMFORT; ACROMEGALY; ADJUVANT THERAPY; ARTHROPATHY; ARTICLE; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; COLON ADENOMA; COLONOSCOPY; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; CONTRAST ENHANCEMENT; DIAGNOSTIC VALUE; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GALLSTONE; GROWTH HORMONE BLOOD LEVEL; HUMAN; HYPERTENSION; HYPOGONADISM; HYPOPHYSIS ADENOMA; HYPOPITUITARISM; HYPOTHYROIDISM; INCIDENCE; METABOLIC DISORDER; MORTALITY; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; ORAL GLUCOSE TOLERANCE TEST; PATHOGENESIS; POLYSOMNOGRAPHY; PREVALENCE; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; SLEEP APNEA SYNDROME; THERAPY RESISTANCE; TRANSSPHENOIDAL HYPOPHYSECTOMY; TREATMENT CONTRAINDICATION; TREATMENT OUTCOME;

ACROMEGALY; ADENOMA; ALGORITHMS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; COMBINED MODALITY THERAPY; DOPAMINE AGONISTS; GLUCOSE TOLERANCE TEST; GROWTH HORMONE-SECRETING PITUITARY ADENOMA; HORMONE ANTAGONISTS; HUMAN GROWTH HORMONE; HUMANS; HYPOPHYSECTOMY; INSULIN-LIKE GROWTH FACTOR I; RADIOTHERAPY, ADJUVANT; RESPIRATION DISORDERS; SLEEP APNEA SYNDROMES; SOMATOSTATIN; TREATMENT OUTCOME; UP-REGULATION;

EID: 34249937419     PISSN: 1386341X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11102-006-0409-4     Document Type: Article

References (23)

1. Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, Veldhuis J, Wass J, Von Werder K, Melmed S (2000) Criteria for cure of acromegaly: A consensus statement. J Clin Endocrinol Metab 85:526-529
2. Trainer PJ (2002) Editorial: Acromegaly-consensus, what consensus? J Clin Endocrinol Metab 87:3534-3536
3. Giustina A, Casanueva FF, Cavagnini F, Chanson P, Clemmons D, Frohman LA, Gaillard R, Ho K, Jaquet P, Kleinberg DL, Lamberts SW, Lombardi G, Sheppard M, Strasburger CJ, Vance ML, Wass JA, Melmed S; The Pituitary Society and the European Neuroendocrine Association (2003) Diagnosis and treatment of acromegaly complications. J Endocrinol Invest 26:1242-1247
4. Colao A, Ferone D, Marzullo P, Lombardi G (2004) Systemic complications of acromegaly: Epidemiology, pathogenesis, and management. Endocr Rev 25:102-152
5. Sheppard MC (2003) Primary medical therapy for acromegaly. Clin Endocrinol (Oxf) 58:387-399
6. Melmed S, Casanueva FF, Cavagnini F, Chanson P, Frohman L, Grossman A, Ho K, Kleinberg D, Lamberts S, Laws E, Lombardi G, Vance ML, Werder KV, Wass J, Giustina A; Acromegaly Treatment Consensus Workshop Participants (2002) Guidelines for acromegaly management. J Clin Endocrinol Metab 87:4054-4058
7. Kopchick JJ, Parkinson C, Stevens EC, Trainer PJ (2002) Growth hormone receptor antagonists: Discovery, development, and use in patients with acromegaly. Endocr Rev 23:623-646
8. Freda PU (2002) Somatostatin analogs in acromegaly. J Clin Endocrinol Metab 87:3013-3018
9. Van Der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, Klibanski A, Herman-Bonert V, Melmed S, Vance ML, Freda PU, Stewart PM, Friend KE, Clemmons DR, Johannsson G, Stavrou S, Cook DM, Phillips LS, Strasburger CJ, Hackett S, Zib KA, Davis RJ, Scarlett JA, Thorner MO (2001) Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 358:1754-1759
10. Wass JA (2003) Radiotherapy in acromegaly: A protagonists viewpoint. Clin Endocrinol (Oxf) 58:128-131
11. Barkan AL (2003) Radiotherapy in acromegaly: The argument against. Clin Endocrinol (Oxf) 58:132-135
12. Thorner MO (2003) Controversy: Radiotherapy for acromegaly. Clin Endocrinol (Oxf) 58:136-137
13. Swords FM, Allan CA, Plowman PN, Sibtain A, Evanson J, Chew SL, Grossman AB, Besser GM, Monson JP (2003) Stereotactic radiosurgery XVI: A treatment for previously irradiated pituitary adenomas. J Clin Endocrinol Metab 88:5334-5340
14. Landolt AM, Haller D, Lomax N, Scheib S, Schubiger O, Siegfried J, Wellis G (2000) Octreotide may act as a radioprotective agent in acromegaly. J Clin Endocrinol Metab 85:1287-1289
15. Newman CB, Melmed S, George A, Torigian D, Duhaney M, Snyder P, Young W, Klibanski A, Molitch ME, Gagel R, Sheeler L, Cook D, Malarkey W, Jackson I, Vance ML, Barkan A, Frohman L, Kleinberg DL (1998) Octreotide as primary therapy for acromegaly. J Clin Endocrinol Metab 83:3034-3040
16. Colao A, Ferone D, Marzullo P, Cappabianca P, Cirillo S, Boerlin V, Lancranjan I, Lombardi G (2001) Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J Clin Endocrinol Metab 86:2779-2786
17. Jaquet P, Cortet-Rudelli Ch, Sassolas G, Morange-Ramos I, Chanson P, Brue T, Andrieu JM, Beckers A, Bertherat J, Borson-Chazot F, Brassier G, Caron P, Cogne M, Cottier JP, Delemer B, Dufour H, Enjalbert A, Figarella-Branger D, Gaillard R, Gueydan M, Jan M, Kuhn JM, Raingeard I, Regis J, Roger P, Rohmer V, Sadoul JL, Saveanu A, Tabarin A, Travers N, Trouillas J French Acromegly Registry (2003) Therapeutic strategies in somatotroph adenomas with extrasellar extension: Role of the medical approach, a consensus study of the French Acromegaly Registry. Ann Endocrinol 64:434-441
18. Ben-Shlomo A, Melmed S (2003) Clinical review 154: The role of pharmacotherapy in perioperative management of patients with acromegaly. J Clin Endocrinol Metab 88:963-968
19. Clemmons DR, Chihara K, Freda PU, Ho KK, Klibanski A, Melmed S, Shalet SM, Strasburger CJ, Trainer PJ, Thorner MO (2003) Optimizing control of acromegaly: Integrating a growth hormone receptor antagonist into the treatment algorithm. J Clin Endocrinol Metab 88:4759-4767
20. Shalet SM (2004) Biochemical monitoring of disease activity after surgery for acromegaly. J Clin Endocrinol Metab 89:492-494
21. Gullu S, Keles H, Delibasi T, Tonyukuk V, Kamel N, Erdogan G (2004) Remission criteria for the follow-up of patients with acromegaly. Eur J Endocrinol 150:465-471
22. Serri O, Beauregard C, Hardy J (2004) Long-term biochemical status and disease-related morbidity in 53 postoperative patients with acromegaly. J Clin Endocrinol Metab 89:658-661
23. Freda PU, Nuruzzaman AT, Reyes CM, Sundeen RE, Post KD (2004) Significance of "abnormal" nadir growth hormone levels after oral glucose in postoperative patients with acromegaly in remission with normal insulin-like growth factor-I levels. J Clin Endocrinol Metab 89:495-500